3-FEA

3-fluoro-N-ethylamphetamine

Sources

5 strong · 12 moderate · 5 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

128/130 (98%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	15 mg	15 mg	low
Low	20–35 mg	20–35 mg	low
Common	35–70 mg	35–70 mg	low
Strong	70–90 mg	70–90 mg	low
Heavy	90+ mg	90+ mg	low
Editorial	Values from existing DB / community consensus (PsychonautWiki). No clinical dosing data exist for 3-FEA. Ranges align with mass-dose expectations for fluoroamphetamine/entactogen class (comparable to MDMA 75-125mg, 4-FA 75-150mg).
	ReasoningReasoning Values from existing DB / community consensus (PsychonautWiki). No clinical dosing data exist for 3-FEA. Ranges align with mass-dose expectations for fluoroamphetamine/entactogen class (comparable to MDMA 75-125mg, 4-FA 75-150mg). Evidence basis: community_consensus_large

insufflatedtrace

Field	Published	AI Proposed	Confidence
Threshold	15 mg	15 mg	low
Low	20–35 mg	20–35 mg	low
Common	35–60 mg	35–60 mg	low
Strong	60–80 mg	60–80 mg	low
Heavy	80+ mg	80+ mg	low
Editorial	Base values from existing DB / community consensus (PsychonautWiki). FLAG: Original source lists strong as 50-60mg which overlaps entirely with common (35-60mg) — this is a data quality error. Adjusted strong range to 60-80mg and heavy to 80+ to create meaningful tier separation. Editorial review strongly recommended.
	ReasoningReasoning Base values from existing DB / community consensus (PsychonautWiki). FLAG: Original source lists strong as 50-60mg which overlaps entirely with common (35-60mg) — this is a data quality error. Adjusted strong range to 60-80mg and heavy to 80+ to create meaningful tier separation. Editorial review strongly recommended. Evidence basis: community_consensus_large

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	20–60 minutes	20–60 minutes	low
Editorial	Community consensus (PsychonautWiki). No clinical PK data for 3-FEA. Consistent with 4-FA Tmax ~2h (Toennes 2019).
	ReasoningReasoning Community consensus (PsychonautWiki). No clinical PK data for 3-FEA. Consistent with 4-FA Tmax ~2h (Toennes 2019). Evidence basis: community_consensus_large
Come uptrace	30–60 minutes	30–60 minutes	low
Editorial	Community consensus (PsychonautWiki). No clinical data.
	ReasoningReasoning Community consensus (PsychonautWiki). No clinical data. Evidence basis: community_consensus_large
Peaktrace	1.5–2.5 hours	1.5–2.5 hours	low
Editorial	Community consensus (PsychonautWiki). No clinical data.
	ReasoningReasoning Community consensus (PsychonautWiki). No clinical data. Evidence basis: community_consensus_large
Totaltrace	4–6 hours	4–6 hours	low
Editorial	Community consensus (PsychonautWiki). Represents subjective experience duration onset through offset, not including aftereffects.
	ReasoningReasoning Community consensus (PsychonautWiki). Represents subjective experience duration onset through offset, not including aftereffects. Evidence basis: community_consensus_large
After effectstrace	6–12 hours	6–12 hours	low
Editorial	Community consensus (PsychonautWiki). Insomnia and residual stimulation prominent. Consistent with expected 8-9h plasma half-life from 4-FA analogy (Toennes 2019).
	ReasoningReasoning Community consensus (PsychonautWiki). Insomnia and residual stimulation prominent. Consistent with expected 8-9h plasma half-life from 4-FA analogy (Toennes 2019). Evidence basis: community_consensus_large
Offsettrace	2–3 hours	2–3 hours	low
Editorial	Community consensus (PsychonautWiki). No clinical data.
	ReasoningReasoning Community consensus (PsychonautWiki). No clinical data. Evidence basis: community_consensus_large

insufflated

Field	Published	AI Proposed	Confidence
Totaltrace	1–2 hours	1–2 hours	low
Editorial	Community consensus (PsychonautWiki). Short subjective duration onset through offset.
	ReasoningReasoning Community consensus (PsychonautWiki). Short subjective duration onset through offset. Evidence basis: community_consensus_large
Onsettrace	5–15 minutes	5–15 minutes	low
Editorial	Community consensus (PsychonautWiki). Rapid absorption via nasal mucosa. No clinical data.
	ReasoningReasoning Community consensus (PsychonautWiki). Rapid absorption via nasal mucosa. No clinical data. Evidence basis: community_consensus_large
Come uptrace	5–10 minutes	5–10 minutes	low
Editorial	Community consensus (PsychonautWiki). Fast escalation characteristic of insufflated stimulants.
	ReasoningReasoning Community consensus (PsychonautWiki). Fast escalation characteristic of insufflated stimulants. Evidence basis: community_consensus_large
Peaktrace	30–60 minutes	30–60 minutes	low
Editorial	Community consensus (PsychonautWiki). Substantially shorter than oral peak.
	ReasoningReasoning Community consensus (PsychonautWiki). Substantially shorter than oral peak. Evidence basis: community_consensus_large
Offsettrace	30–60 minutes	30–60 minutes	low
Editorial	Community consensus (PsychonautWiki). Rapid decline drives compulsive redosing urge.
	ReasoningReasoning Community consensus (PsychonautWiki). Rapid decline drives compulsive redosing urge. Evidence basis: community_consensus_large
After effectstrace	1–3 hours	1–3 hours	low
Editorial	Community consensus (PsychonautWiki). Shorter aftereffects than oral but nasal congestion and mild comedown persist.
	ReasoningReasoning Community consensus (PsychonautWiki). Shorter aftereffects than oral but nasal congestion and mild comedown persist. Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	moderate	moderate	low
Chronic	moderate	moderate	low
Organs Affected	cardiovascular, neurological, thermoregulatory	cardiovascular, neurological, thermoregulatory	low
Editorial	All human toxicity claims class-extrapolated from 4-FA (reference compound). Evidence discount applied: raw findings suggest high acute CV toxicity from 4-FA data, downgraded one level to moderate for 3-FEA due to (1) no direct 3-FEA human data and (2) greater serotonin selectivity may theoretically reduce catecholamine burden. Confidence low per discount rule.
	ReasoningReasoning All human toxicity claims class-extrapolated from 4-FA (reference compound). Evidence discount applied: raw findings suggest high acute CV toxicity from 4-FA data, downgraded one level to moderate for 3-FEA due to (1) no direct 3-FEA human data and (2) greater serotonin selectivity may theoretically reduce catecholamine burden. Confidence low per discount rule. Evidence basis: structural_analogy

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	moderate	moderate	medium
Psychological	moderate	moderate	medium
Compulsive Redosing	moderate	moderate	medium
Dose Escalation	moderate	moderate	medium
Editorial	Physical dependence directly demonstrated by Jo et al. 2024 in mice (withdrawal hyperactivity, depression-like behavior, somatic signs). Psychological dependence and compulsive redosing inferred from class pharmacology (Rothman 2001 DAT/SERT model) and community consensus. Moderate rather than high ratings reflect serotonin-dominant profile attenuating pure dopaminergic reinforcement.
	ReasoningReasoning Physical dependence directly demonstrated by Jo et al. 2024 in mice (withdrawal hyperactivity, depression-like behavior, somatic signs). Psychological dependence and compulsive redosing inferred from class pharmacology (Rothman 2001 DAT/SERT model) and community consensus. Moderate rather than high ratings reflect serotonin-dominant profile attenuating pure dopaminergic reinforcement. Evidence basis: animal_study

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	moderate	moderate	medium
Symptoms	hyperactivity, depression-like behavior, somatic withdrawal signs, anxiety-like behavior, insomnia, fatigue, anhedonia	hyperactivity, depression-like behavior, somatic withdrawal signs, anxiety-like behavior, insomnia, fatigue, anhedonia	medium
Fatal	No	No	medium
Medical Supervision	Not required	Not required	medium
Editorial	Jo et al. 2024 assessed withdrawal at 16h and 40h post-cessation in mice, finding persistent withdrawal signs at both timepoints. Somatic withdrawal, hyperactivity (open field + EPM), and depression-like behavior (FST) documented. Human withdrawal duration unknown; 3-day total estimated from amphetamine class analogy. Not life-threatening by class.
	ReasoningReasoning Jo et al. 2024 assessed withdrawal at 16h and 40h post-cessation in mice, finding persistent withdrawal signs at both timepoints. Somatic withdrawal, hyperactivity (open field + EPM), and depression-like behavior (FST) documented. Human withdrawal duration unknown; 3-day total estimated from amphetamine class analogy. Not life-threatening by class. Evidence basis: animal_study

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	2.5 days	2.5 days	low
Full Reset	5 days	5 days	low
Cross-tolerances	amphetamine, MDMA, cathinones, 4-FA, 3-FA, serotonergic compounds	amphetamine, MDMA, cathinones, 4-FA, 3-FA, serotonergic compounds	low
Editorial	Values from existing DB / community consensus (PsychonautWiki). No published tolerance kinetics study exists for 3-FEA. Cross-tolerance list expanded from work-notes to include specific compounds with shared mechanism. Mechanism is class-level established pharmacology for MRAs.
	ReasoningReasoning Values from existing DB / community consensus (PsychonautWiki). No published tolerance kinetics study exists for 3-FEA. Cross-tolerance list expanded from work-notes to include specific compounds with shared mechanism. Mechanism is class-level established pharmacology for MRAs. Evidence basis: community_consensus_large

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
other MAOI therapytrace	absolute	absolute	high
Editorial	Well-established class-level lethal interaction for all amphetamine-type MRAs. Luethi & Liechti 2020 review confirms. No 3-FEA-specific case data but mechanism is absolute.
	ReasoningReasoning Well-established class-level lethal interaction for all amphetamine-type MRAs. Luethi & Liechti 2020 review confirms. No 3-FEA-specific case data but mechanism is absolute.
pregnancy breastfeeding Pregnancytrace	relative	relative	low
Editorial	Class-level contraindication for all amphetamine-type stimulants. No substance-specific data. Confidence low due to complete absence of 3-FEA reproductive studies.
	ReasoningReasoning Class-level contraindication for all amphetamine-type stimulants. No substance-specific data. Confidence low due to complete absence of 3-FEA reproductive studies.
psychiatric History of psychosis or maniatrace	relative	relative	medium
Editorial	Well-established class-level risk for all amphetamine-type stimulants. No 3-FEA-specific data but mechanism is pharmacologically certain.
	ReasoningReasoning Well-established class-level risk for all amphetamine-type stimulants. No 3-FEA-specific data but mechanism is pharmacologically certain.
other Tramadoltrace	absolute	absolute	high
Editorial	Pharmacologically well-supported per Reeves & Burke 2008 and Pergolizzi et al. 2022. Seed data classifies this as lethal. Mechanism confirmed.
	ReasoningReasoning Pharmacologically well-supported per Reeves & Burke 2008 and Pergolizzi et al. 2022. Seed data classifies this as lethal. Mechanism confirmed.
cardiovascular Cardiovascular diseasetrace	absolute	absolute	medium
Editorial	Structural analogy with 4-FA (Gresnigt 2022) and confirmed pharmacological mechanism of NE/DA release. Classified absolute due to severity of documented 4-FA outcomes.
	ReasoningReasoning Structural analogy with 4-FA (Gresnigt 2022) and confirmed pharmacological mechanism of NE/DA release. Classified absolute due to severity of documented 4-FA outcomes.
other Concurrent serotonergic medicationstrace	relative	relative	medium
Editorial	Class-level pharmacological interaction for all serotonin-releasing agents. Well-established in MDMA literature. No 3-FEA-specific case data.
	ReasoningReasoning Class-level pharmacological interaction for all serotonin-releasing agents. Well-established in MDMA literature. No 3-FEA-specific case data.
neurological Seizure disorderstrace	relative	relative	medium
Editorial	Class-level risk for amphetamine-type stimulants. No 3-FEA-specific seizure reports but pharmacological mechanism is established.
	ReasoningReasoning Class-level risk for amphetamine-type stimulants. No 3-FEA-specific seizure reports but pharmacological mechanism is established.
hepatic Hepatic impairmenttrace	relative	relative	low
Editorial	Inferred from amphetamine-class CYP2D6/3A4 metabolism. No 3-FEA-specific PK data confirm hepatic dependence. Low confidence due to entirely inferential basis.
	ReasoningReasoning Inferred from amphetamine-class CYP2D6/3A4 metabolism. No 3-FEA-specific PK data confirm hepatic dependence. Low confidence due to entirely inferential basis.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1200–3600 sec(i=0.15)	1200–3600 sec(i=0.15)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes. Evidence basis: community_consensus_large
Come uptrace	1800–3600 sec(i=0.50)	1800–3600 sec(i=0.50)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes. Evidence basis: community_consensus_large
Peaktrace	5400–9000 sec(i=1.00)	5400–9000 sec(i=1.00)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes. Evidence basis: community_consensus_large
Resolutiontrace	7200–10800 sec(i=0.40)	7200–10800 sec(i=0.40)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes. Evidence basis: community_consensus_large
Afterglowtrace	21600–43200 sec(i=0.10)	21600–43200 sec(i=0.10)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 20-60min, come_up 30-60min, peak 1.5-2.5h, offset 2-3h, aftereffects 6-12h. Phase descriptions from work-notes and article prose. No clinical PK data exist for 3-FEA. Intensity weights from work-notes. Evidence basis: community_consensus_large

insufflated

Field	Published	AI Proposed	Confidence
Onsettrace	300–900 sec(i=0.30)	300–900 sec(i=0.30)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data. Evidence basis: community_consensus_large
Come uptrace	300–600 sec(i=0.70)	300–600 sec(i=0.70)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data. Evidence basis: community_consensus_large
Peaktrace	1800–3600 sec(i=1.00)	1800–3600 sec(i=1.00)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data. Evidence basis: community_consensus_large
Resolutiontrace	1800–3600 sec(i=0.30)	1800–3600 sec(i=0.30)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data. Evidence basis: community_consensus_large
Afterglowtrace	3600–10800 sec(i=0.10)	3600–10800 sec(i=0.10)	low
Editorial	Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data.
	ReasoningReasoning Duration values from community consensus (PsychonautWiki): onset 5-15min, come_up 5-10min, peak 30-60min, offset 30-60min, aftereffects 1-3h, total 1-2h. Work-notes describe insufflated as more stimulant-forward with higher redosing urge. No clinical data. Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace

low

Minimal perceptible effects emerge at this level — a subtle increase in alertness, mild mood brightening, and faint peripheral stimulation detectable as a slight heart rate elevation. No significant entactogenic component manifests. Physically, effects are limited to mild sympathetic activation: marginally increased pulse, very slight pupil change, and a whisper of appetite reduction. Most users would not confidently distinguish this from placebo without prior experience with the compound. Functional impairment is negligible. Sleep may be slightly delayed if taken in the evening. Duration of noticeable effects is brief — under 2 hours for most users.

Editorial

Work-notes threshold description expanded. All values from community consensus (PsychonautWiki). No clinical threshold data exist for 3-FEA.

Reasoning

Work-notes threshold description expanded. All values from community consensus (PsychonautWiki). No clinical threshold data exist for 3-FEA.

Evidence basis: community_consensus_large

lighttrace

low

Noticeable stimulation and mood elevation become clearly perceptible. A mild empathogenic warmth begins to emerge — subtle emotional openness and social ease without overwhelming intensity. Music may sound slightly enhanced. Appetite suppression becomes apparent, slight pupil dilation is detectable, and gentle body warmth develops. Heart rate elevation is mild but present. Social enhancement manifests without significant cognitive impairment — conversation flows more easily. Functional capacity remains largely intact though driving is inadvisable. Effects last 3-4 hours orally with mild aftereffects. Sleep disruption is possible if dosed within 6 hours of bedtime.

Editorial

Work-notes light tier outline expanded with substance-specific texture from article prose. Community consensus source (PsychonautWiki). No clinical data.

Reasoning

Work-notes light tier outline expanded with substance-specific texture from article prose. Community consensus source (PsychonautWiki). No clinical data.

Evidence basis: community_consensus_large

commontrace

low

The full dual stimulant-entactogen profile expresses clearly. Emotional enhancement, empathy, and tactile euphoria become prominent. Body warmth radiates outward, music appreciation deepens substantially, and social connection feels effortless and genuine. The paradoxical sedation-over-stimulation character becomes apparent — mental energy coexists with physical relaxation. Moderate sympathetic activation produces noticeable tachycardia and blood pressure elevation. Appetite suppression is pronounced, bruxism may begin, pupil dilation is obvious, and sweating increases. Dry mouth develops. The body high carries a serotonergic warmth distinct from pure stimulant tension. Commitment is 4-6 hours for the primary experience, with 6-12 hours of residual aftereffects including insomnia and mild cognitive fatigue. Insufflated duration is dramatically shorter (1-2 hours total) with a more stimulant-forward character.

Editorial

Work-notes common tier expanded. Core of the 3-FEA experience based on community consensus and MDMA/4-FA structural analogy. PsychonautWiki reports paradoxical sedation.

Reasoning

Work-notes common tier expanded. Core of the 3-FEA experience based on community consensus and MDMA/4-FA structural analogy. PsychonautWiki reports paradoxical sedation.

Evidence basis: community_consensus_large

strongtrace

low

Intensified entactogenic and stimulant effects dominate the experience. Euphoria, empathy enhancement, and tactile pleasure reach near-maximum expression. Emotional openness can feel overwhelming. Music enhancement becomes immersive. Disinhibition is pronounced. Bruxism and jaw tension become persistent and uncomfortable. Cardiovascular activation is significant — elevated heart rate and blood pressure require attention. Temperature dysregulation risk increases noticeably; sweating is heavy. The comedown becomes markedly more pronounced than at common doses, with depression, irritability, and cognitive fatigue more likely. Recovery period extends substantially. Insomnia of 8+ hours is common. The risk-benefit ratio shifts unfavorably as cardiovascular stress and serotonergic neurotoxicity concerns escalate. Compulsive redosing urge may intensify at this level.

Editorial

Work-notes strong tier expanded. Cardiovascular risk inference from 4-FA data (Gresnigt 2022, de Sousa Fernandes Perna 2018). Community consensus on comedown severity.

Reasoning

Work-notes strong tier expanded. Cardiovascular risk inference from 4-FA data (Gresnigt 2022, de Sousa Fernandes Perna 2018). Community consensus on comedown severity.

Evidence basis: community_consensus_large

heavytrace

low

Overwhelming stimulation with significant risk of anxiety, paranoia, and panic. The entactogenic warmth may be overridden by sympathomimetic distress. Cognitive impairment replaces enhancement. Thought disorganization and confusion may emerge. Severe cardiovascular stress constitutes the primary acute danger — 4-FA data show 40% rates of serious cardiovascular events at high doses (Takotsubo, MI, cerebral hemorrhage). Hyperthermia risk is markedly elevated. Pronounced bruxism, profuse sweating, and temperature dysregulation are expected. Seizure threshold may be lowered. Significant post-experience dysphoria, depression, and anhedonia are likely, potentially persisting several days. Compulsive redosing urge at this dose level can drive dangerous total exposure. This dose range carries meaningful risk of medical emergency without clear experiential benefit over common-to-strong dosing.

Editorial

Work-notes heavy tier expanded. Cardiovascular risk from 4-FA structural analogy (Gresnigt 2022). Psychological risks from amphetamine class pharmacology. Community reports of severe comedowns.

Reasoning

Work-notes heavy tier expanded. Cardiovascular risk from 4-FA structural analogy (Gresnigt 2022). Psychological risks from amphetamine class pharmacology. Community reports of severe comedowns.

Evidence basis: structural_analogy

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +0 / −0 citations

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

5 strong · 12 moderate · 5 weak

[1]
moderate
Withdrawal from 3-Fluoroethamphetamine induces hyperactivity and depression-like behaviors in male mice
Jo C, Joo H, Lim NY, Park SJ, Choi SO · 2024 · Journal of Neuroscience Research
doi.org/10.1002/jnr.25251 pubmed 37818759no claims checked
[2]
strong
Designer drugs: mechanism of action and adverse effects
Luethi D, Liechti ME · 2020 · Archives of Toxicology
doi.org/10.1007/s00204-020-02693-7 pubmed 32249347no claims checked
[3]
moderate
Identification and characterization of the new psychoactive substance 3-fluoroethamphetamine in seized material
Yanini Á, Armenta S, Esteve-Turrillas F, Galipienso N, de la Guardia M · 2018 · Forensic Toxicology
doi.org/10.1007/s11419-018-0416-yno claims checked
[4]
moderate
Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
Liechti ME · 2015 · Swiss Medical Weekly
doi.org/10.4414/smw.2015.14043 pubmed 25588018no claims checked
[5]
weak
3-FEA
2024
linkno claims checked
[6]
moderate
4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis
Gresnigt FMJ, Snik A, Franssen EJF, Vanhommerig JW, de Lange DW, Riezebos RK · 2022 · Journal of the American College of Emergency Physicians Open
doi.org/10.1002/emp2.12813 pubmed 36187507no claims checked
[7]
moderate
Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs
Schmidt CJ · 1987 · European Journal of Pharmacology
pubmed 2885204no claims checked
[8]
moderate
Tramadol: basic pharmacology and emerging concepts
Reeves RR, Burke RS · 2008 · Drugs of Today
doi.org/10.1358/dot.2008.44.11.1289441 pubmed 19180260no claims checked
[9]
weak
3-Fluoroethamphetamine
2024
linkno claims checked
[10]
weak
3-Fluoroethamphetamine - NCATS Inxight Drugs
2024
linkno claims checked
[11]
weak
A simple and isocratic protein-based high performance liquid chromatography method for the enantioseparation of amphetamine derivatives
2021
linkno claims checked
[12]
moderate
Locomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats
Anchondo O, Shetty RA, Gatch MB · 2025 · Journal of Pharmacology and Experimental Therapeutics
doi.org/10.1016/j.jpet.2025.103617 pubmed 40553972no claims checked
[13]
moderate
Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A · 2017 · Journal of Pharmacology and Experimental Therapeutics
doi.org/10.1124/jpet.116.236349 pubmed 27799294no claims checked
[14]
strong
Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion
Toennes SW, Schneider D, Pogoda W, Paulke A, Wunder C, Theunissen EL, Kuypers KPC, de Sousa Fernandes Perna E, Ramaekers JG · 2019 · Drug Testing and Analysis
doi.org/10.1002/dta.2595 pubmed 30912312no claims checked
[15]
moderate
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS · 2001 · Synapse
pubmed 11071707no claims checked
[16]
strong
Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M · 2016 · Frontiers in Neuroscience
doi.org/10.3389/fnins.2016.00153 pubmed 27147945no claims checked
[17]
strong
A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State
Kuypers KPC, De Sousa Fernandes Perna EB, Theunissen EL, Toennes SW, Mason NL, Hutten NRPW, Ramaekers JG · 2019 · Journal of Psychoactive Drugs
doi.org/10.1080/02791072.2019.1569286 pubmed 30676284no claims checked
[18]
moderate
4-Fluoroamphetamine in the Netherlands: more than a one-night stand
Linsen F, Koning RP, van Laar M, Niesink RJ, Koeter MW, Brunt TM · 2015 · Addiction
doi.org/10.1111/add.12932 pubmed 25808511no claims checked
[19]
moderate
Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues
Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML · 2014 · British Journal of Pharmacology
doi.org/10.1111/bph.13030 pubmed 25438806no claims checked
[20]
strong
Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
de Sousa Fernandes Perna EB, Theunissen EL, Dolder PC, Mason NL, Hutten NRPW, Toennes SW, Kuypers KPC, Ramaekers JG · 2018 · Frontiers in Pharmacology
doi.org/10.3389/fphar.2018.00713 pubmed 30050434no claims checked
[21]
moderate
Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.
Pergolizzi J, Magnusson P, Coluzzi F, Breve F, LeQuang JAK, Varrassi G · 2022 · Cureus
doi.org/10.7759/cureus.26000 pubmed 35855248no claims checked
[22]
weak
Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
Drug Enforcement Administration (DEA) · 2026
linkno claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

89 links · 87 approved · 35 audited2/89 with evidence basis

interactions

10 approved pairs0/10 graded

3-FEA

Value Provenance

Dosing

oraltrace →

insufflatedtrace →

Duration

oral

insufflated

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

insufflated

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

oraltrace

insufflatedtrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace